IMRX · Immuneering Corporation

Summary

Immuneering Corporation announced Q4 and full-year 2025 financial results, reporting 64% overall survival at 12 months in its Phase 2a trial of atebimetinib + mGnP in first-line pancreatic cancer patients, cash of $217 million extending runway into 2029, and alignment with FDA/EMA on Phase 3 trial design with first patient dosing mid-2026.

Key takeaways

• Event Type: Earnings Release and Clinical Updates (Items: 2.02)